Ayala Pharmaceuticals, Inc. AYLA
We take great care to ensure that the data presented and summarized in this overview for Ayala Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AYLA
View allLatest Institutional Activity in AYLA
Top Purchases
Top Sells
About AYLA
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
Insider Transactions at AYLA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 19
2023
|
A Moon Growth Fund Limited Partnership > 10% Shareholder |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,991,473
-100.0%
|
-
|
|
Jan 19
2023
|
Roni Mamluk President & CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
265,345
-100.0%
|
-
|
|
Jan 19
2023
|
Gary B. Gordon Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
58,520
-100.0%
|
-
|
|
Jan 19
2023
|
Yossi Maimon CFO, Secretary and Treasurer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
69,872
-100.0%
|
-
|
|
Jan 19
2023
|
David Sidransky Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
250
-100.0%
|
-
|
|
May 16
2022
|
Roni Mamluk President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
120,000
+31.14%
|
-
|
|
May 16
2022
|
Gary B. Gordon Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+46.07%
|
-
|
|
May 16
2022
|
Yossi Maimon CFO, Secretary and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+41.71%
|
-
|
|
Feb 24
2021
|
Gary B. Gordon Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,000
-26.04%
|
$51,000
$17.46 P/Share
|
|
Feb 24
2021
|
Gary B. Gordon Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+20.66%
|
$15,000
$5.16 P/Share
|
|
Feb 24
2021
|
Roni Mamluk President & CEO |
SELL
Open market or private sale
|
Direct |
10,800
-6.92%
|
$183,600
$17.4 P/Share
|
|
Feb 23
2021
|
Roni Mamluk President & CEO |
SELL
Open market or private sale
|
Direct |
7,126
-4.36%
|
$121,142
$17.89 P/Share
|
|
Feb 22
2021
|
Roni Mamluk President & CEO |
SELL
Open market or private sale
|
Direct |
15,200
-8.52%
|
$288,800
$19.86 P/Share
|
|
Jan 21
2021
|
Roni Mamluk President & CEO |
SELL
Open market or private sale
|
Direct |
1,406
-0.78%
|
$21,090
$15.04 P/Share
|
|
Jan 20
2021
|
Gary B. Gordon Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,000
-26.04%
|
$45,000
$15.03 P/Share
|
|
Jan 20
2021
|
Gary B. Gordon Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+20.66%
|
$15,000
$5.16 P/Share
|
|
Jan 20
2021
|
Roni Mamluk President & CEO |
SELL
Open market or private sale
|
Direct |
19,466
-9.77%
|
$291,990
$15.03 P/Share
|
|
Jan 04
2021
|
Roni Mamluk President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
34,080
+14.6%
|
-
|
|
Jan 04
2021
|
Yossi Maimon CFO, Secretary and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
8,520
+30.01%
|
-
|
|
Jan 04
2021
|
Gary B. Gordon Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,520
+50.0%
|
-
|